Altimmune (ALT) Stock Price
Altimmune Price
Revenue at Altimmune has contracted by 18.2% per year over the past 19 years to 41,000.00 USD. For Altimmune, the net margin of -214,861.0% is down versus -2,201.6% a few years ago. At today's price the dividend yield works out to roughly 42,794.12%. The consensus 12-month price target for Altimmune is 6.25 USD, about 206.4% above where the stock trades today. Of 15 analysts, 13 rate the stock a buy — an overall Buy consensus.
Altimmune stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Altimmune business model & stock analysis
Frequently asked questions about Altimmune
Altimmune Inc is a biopharmaceutical company with a business model focused on developing and commercializing novel immunotherapeutic products. The company aims to address various diseases and medical conditions through innovative vaccine technologies and immune modulation platforms. Altimmune Inc is committed to advancing its proprietary pipeline, leveraging its expertise in immunology and vaccine development. With a strong emphasis on research and development, Altimmune Inc strives to bring novel treatments to market that can positively impact the lives of patients worldwide.
Altimmune Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Altimmune Inc in the market include companies such as Inovio Pharmaceuticals, VBI Vaccines, Novavax, and Moderna Inc.
Altimmune Inc is a biopharmaceutical company focused on developing and commercializing immunotherapeutic products. Founded in 1997, Altimmune has a rich history of innovation in the field of immunology. The company specializes in the development of novel vaccines and immune-modulating therapies to combat infectious diseases. Altimmune's proprietary platform technologies enable the rapid design and development of next-generation immunotherapies. With a strong commitment to scientific research and development, Altimmune aims to transform the treatment landscape by addressing unmet medical needs. With its experienced team and extensive portfolio, Altimmune Inc is poised to make a significant impact on the global healthcare industry.
Altimmune Inc has achieved significant milestones in its journey. Some noteworthy accomplishments include the successful completion of Phase 2 clinical trials for its lead product candidate, AdCOVID, a single-dose intranasal COVID-19 vaccine. The company has also demonstrated the effectiveness of NasoShield, a vaccine for anthrax, in preclinical studies. Altimmune Inc has further enhanced its portfolio by acquiring Spitfire Pharma, a biopharmaceutical company focused on liver diseases. Additionally, the company has established collaborations with leading organizations, including the University of Alabama and the National Institutes of Health, to advance its innovative pipeline. These milestones highlight Altimmune Inc's dedication to advancing novel therapies and its potential for future growth in the biopharmaceutical industry.
Altimmune Inc is primarily present in the United States.
Altimmune Inc represents a core value of innovation and commitment to transformative medical solutions. With a strong corporate philosophy focused on advancing novel therapies, Altimmune Inc continuously strives to improve patient outcomes through groundbreaking immunotherapies. The company's dedication to scientific excellence and rigorous research enables the development of cutting-edge vaccine candidates, including intranasal vaccines to combat infectious diseases. Altimmune Inc's vision encompasses pioneering approaches in immunology and the goal of addressing unmet medical needs worldwide. By leveraging its expertise, Altimmune Inc remains at the forefront of medical advancements, exemplifying a steadfast commitment to improving global health.
Analysts currently set an average price target of 6.25 USD for the Altimmune stock (median: 6.25 USD), implying +197.6 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Altimmune stock: 13 recommend buying, 2 holding and 0 selling.
Converted at the current exchange rate, the Altimmune share trades at 1.83 EUR (2.04 USD).
The Altimmune share (ALT) is listed on 5 stock exchanges, including: NASDAQ (ALT), London (0A4C.L), Frankfurt (3G0.F), München (3G0.MU), Düsseldorf (3G0.DU).
The company Altimmune Inc. is a biopharmaceutical company specializing in the development of immunotherapies and vaccines for various diseases. Its business model is based on innovative research and development to meet the increasingly complex challenges of the medical industry. The company operates in three business areas - Immundevelopment, Vaxine, and Altimmune UK. Immundevelopment focuses on the research of immunotherapies and viral infections such as hepatitis B, HIV, and influenza. Vaxine develops vaccines against flu, anthrax, MERS, RSV, and COVID-19. Altimmune UK is increasingly focused on the field of neuroscience and oncology. Altimmune is divided into two pillars, immunotherapy and vaccine development. The two pillars work closely together to accelerate and improve the development of therapies and vaccines. In the immunotherapy pillar, treatments are being researched that stimulate the immune system to fight against various diseases. In the vaccine development, Altimmune produces vaccines that induce active immunization against certain diseases. One of Altimmune's most important products is NasoVAX, an intranasally administered flu vaccine. Compared to conventional injectable vaccines, NasoVAX offers faster action and does not require a nurse. NasoShield, an intranasally administered anthrax vaccine, is another well-known product from Altimmune. The company has also developed COVID-19 vaccine candidates that are now being tested in clinical trials. Altimmune aims to develop innovative solutions for serious diseases. The company has a strong commitment to research and development and is committed to continuing its successes in drug development. The company's mission is to ensure the creation of cost-effective solutions and improvement of outcomes for patients. Through the development of novel therapies and vaccines, Altimmune is repeatedly praised as one of the most promising companies in the industry. With a growing product range and a strong research and development department, the company is well-equipped to tackle important medical challenges of the future. In the future, it will be of great importance for Altimmune to continue developing innovative products that meet medical requirements. The industry will evolve through new scientific discoveries and the use of cutting-edge technologies, and Altimmune strives to play a leading role in this transformation.
The revenue cannot currently be calculated for Altimmune.
The expected profit of Altimmune is -40.71 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Altimmune is currently -5.04. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Altimmune stock.
The P/S cannot be calculated for Altimmune currently.
The Eulerpool Quality Score for Altimmune is 3/10.
The ISIN of Altimmune is US02155H2004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Altimmune is A2N5Z6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Altimmune is ALT. The ticker symbol is used to trade Altimmune shares on the stock exchange.
Altimmune stock
Altimmune Peer Group
Altimmune Ticker
Altimmune FIGI
All fundamentals and in-depth analysis of Altimmune
Our stock analysis for Altimmune stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Altimmune. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.